Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Evaxion Biotech ( (EVAX) ) has provided an update.
Evaxion Biotech A/S has announced its Articles of Association, focusing on the issuance of warrants and potential capital increases. The board is authorized to issue warrants and increase share capital up to a nominal value of DKK 9,461,540, aligning with their strategic goals to enhance shareholder value and operational flexibility.
More about Evaxion Biotech
Evaxion Biotech A/S is a biotechnology company that specializes in creating advanced software to develop novel immune therapies and vaccines. It operates under the secondary name NovVac A/S.
YTD Price Performance: 2.81%
Average Trading Volume: 342,920
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $5.14M
See more data about EVAX stock on TipRanks’ Stock Analysis page.
Trending Articles
- Tencent Repurchases $193M Worth of Stock to Support its Share Price
- Don’t Miss Out! Class Action Lawsuit Against Hasbro Inc. (NASDAQ:HAS)
- Microsoft Attracts Analysts’ Buy Ratings Despite High AI Capex Plans
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
